Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Sulcoflex intraocular lens implant for refractive enhancement in pseudophakic patients

Poster Details

First Author: P.Chiam UK

Co Author(s):    S. Quah              

Abstract Details


To evaluate the refractive outcome of aspheric and toric Sulcoflex, a sulcus-fixated intraocular lens (IOL) implant in correcting postcataract surgery ametropia.


Macclesfield District General Hospital and Optegra Manchester Eye Hospital, UK.


The refractive outcome of 9 eyes from 7 patients who had Sulcoflex IOL implant were reviewed retrospectively. Refraction was performed between one to two months after the operation. Four eyes had toric Sulcoflex, of which 3 had spherical error correction as well. The remaining eyes had aspheric Sulcoflex implant to correct spherical error only. The difference in refractive error before and after the IOL implant was analysed using paired Student t-test. The postoperative target refraction for all eyes was emmetropia.


The mean age was 75.2 ± 8.8. The range of preoperative spherical equivalent was between -5.00 to 4.25D. The mean magnitude of preoperative spherical equivalent error was 3.19 ± 1.21D. The Sulcoflex IOL implant reduced the refractive error by 3.11 ± 1.37D. There is no statistical significant difference between the two values (p = 0.692). The range of postoperative spherical equivalent was between -0.75 to 0.88D. Four out of the 9 eyes had refractive errors within 0.5D, and all within 1.00D. The preoperative astigmatism (4 eyes) was 4.00D (range 1.50 to 5.50) and postoperative 0.50D (range 0.00 to 1.50) (p = 0.014). There was no complication during the operation and postoperative visits. All patients were pleased with the unaided visual outcome postoperatively.


The Sulcoflex IOL is an effective way to correct postcataract surgery ametropia. All eyes achieved a significant correction of their residual ametropia. FINANCIAL DISCLOSURE?: No

Back to previous

loading Please wait while information is loading.